Could a nasal spray before labor ward off postpartum depression?

NCT ID NCT07501728

Not yet recruiting Prevention Sponsor: Chengdu Jinjiang Maternity and Child Health Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a single dose of intranasal dexmedetomidine, given just before labor pain relief, can lower the chance of postpartum depression (PPD). Researchers will enroll 270 women having vaginal deliveries and randomly give them either the drug or a placebo. The main goal is to see if fewer women develop PDD symptoms 42 days after giving birth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dexmedetomidine
What this could lead to: If it works, this could offer a simple, non-invasive way to lower the risk of postpartum depression after vaginal delivery.
What could go wrong: This is a small, early-stage trial (270 participants) testing a single dose. The effect may be modest or not statistically significant, and side effects like low heart rate or low blood pressure are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POSTPARTUM DEPRESSION (PPD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

postpartum depression prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POSTPARTUM DEPRESSION (PPD)

Contacts and locations

Locations

Chengdu Jinjiang District Women & Children Health Hospital,

Chengdu, Sichuan, 610011, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.